Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience.
OBJECTIVE
Sarcoma of prostate origin is rare. Historically, long-term survival rates for adult patients with prostate sarcoma are poor. We analyzed the experience of 1 institution with prostate sarcoma during the last 3 decades.


METHODS
The records of 21 patients with prostate sarcoma were reviewed to identify symptoms at presentation, diagnostic procedures, presence and development of metastases, staging evaluation, histological subtype, grade and size of the primary tumor, and treatment sequence, including surgery, and preoperative and postoperative therapies. Several clinicopathological variables were assessed for prognostic importance.


RESULTS
Most patients presented with urinary obstruction. The diagnosis of prostate sarcoma was usually established with ultrasound guided biopsy or transurethral resection. Histological subtypes were leiomyosarcoma in 12, rhabdomyosarcoma in 4, malignant fibrous histiocytoma in 1 and unclassified sarcoma in 4 patients. At last followup, 8 patients had no evidence of disease after a median of 81.5 months (range 10 to 197). The remaining 13 patients died of sarcoma (median survival 18 months, range 3 to 94). The 1, 3 and 5-year actuarial survival rates for all 21 patients were 81%, 43% and 38%, respectively. Factors predictive of long-term survival were negative surgical margins (p = 0.0005) and absence of metastatic disease at presentation (p = 0.0004). Tumor size and grade, and the histological subtype of prostate sarcoma had no significant influence on actuarial survival.


CONCLUSIONS
The long-term disease specific survival rate for adults with prostate sarcoma is poor. Early diagnosis and complete surgical resection offer patients the best chance for cure.
Sexton
W J
WJ
Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Lance
R E
RE
Reyes
A O
AO
Pisters
P W
PW
Tu
S M
SM
Pisters
L L
LL
D006801:Humans; D007890:Leiomyosarcoma / Q000175:diagnosis; D008297:Male; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000401:mortality*; D012208:Rhabdomyosarcoma / Q000175:diagnosis; D012509:Sarcoma / Q000175:diagnosis / Q000401:mortality*; D015996:Survival Rate
D017430:Prostate-Specific Antigen